Fig. 2From: Phase 1b randomized, double-blind study of namilumab, an anti-granulocyte macrophage colony-stimulating factor monoclonal antibody, in mild-to-moderate rheumatoid arthritisChange from baseline in DAS28-CRP with namilumab compared with placebo. *Error bars show upper SE for placebo and lower SE for namilumab. DAS disease activity score, CRP C-reactive protein, SE standard errorBack to article page